ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe
On 12 August 2013, the FDA approved dolutegravir in the US. i-Base reported the news with an article linked to previous clinical trial results that noted not only the potential advantages but also some of the cautions. One of the concerns was how the price, which didn’t accompany the original company press statement, would be …
ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe Read More »